Notice of Special Interest (NOSI): Technologies and Informatics Tools for Cancer Metabolomics

Funding Agency:
National Institutes of Health

This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) is seeking to support development of innovative technologies and informatics tools for metabolomics research by leveraging ongoing programs. Innovative technologies for cancer metabolomics can be supported through the Innovative Molecular Analysis Technologies (IMAT) program and informatics tools for cancer metabolomics can be supported through the Informatics Technology for Cancer Research (ITCR) program.

Metabolomics is the systematic study of chemical reactions occurring in organisms, cells, or tissues that involve small molecule substrates, intermediates, and products of metabolism, called metabolites. These small chemicals play key roles in keeping cells healthy and functioning; thus, improving metabolomics technologies and making them more accessible to researchers could advance cancer research across the basic-translational-clinical cancer research continuum.

NCI administers two unique programs focused on the development of technologies that offer transformative potential for advancing cancer research. The Innovative Molecular Analysis Technologies (IMAT) program supports highly innovative, data-generating platforms and methodologies. The program solicits grant applications for early-stage development of novel tools and methods that enable cancer researchers across the entire spectrum of cancer research. The Informatics Technologies for Cancer Research (ITCR) program supports powerful data analysis, management, and visualization technologies. The program supports research-driven informatics technology development spanning all aspects of cancer research and across the tool development lifecycle.

The NCI seeks to stimulate technology development to facilitate transformational new approaches for cancer metabolomics and lipidomics research through the IMAT and ITCR programs. Therefore, this announcement seeks to address the need for new technologies designed explicitly to overcome technical challenges and advance cancer metabolomics. Such research could include, but is not limited to, launching new and innovative analytical and software platforms, improving the ability of researchers to process more complex samples or increase sample throughput, and/or developing novel computational approaches or tools that facilitate metabolomics data analysis, interpretation, and integration.

This notice applies to due dates on or after June 14, 2022, and subsequent receipt dates through December 31, 2024. 





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

June 16, 2024